Literature DB >> 2874651

The induction of accelerated murine amyloid with human splenic extract. Probable role of amyloid enhancing factor.

J Varga, M S Flinn, T Shirahama, O G Rodgers, A S Cohen.   

Abstract

Amyloid enhancing factor (AEF) is derived from the tissues of pre-amyloidotic and amyloidotic animals and, when transferred, greatly accelerates amyloid induction in the recipient murine models. It has also been reported that similarly accelerated amyloid induction can be achieved in mice by injection of human splenic homogenates from patients with amyloidosis. The present study has attempted to characterize further the mechanism of this "heterologous transfer of amyloid". Treatment of mice with the "tissue homogenate" or the "AEF extract" of AA-, AL- and A prealbumin-laden human spleens followed by daily subcutaneous casein injections induced amyloidosis in an accelerated fashion. The resultant amyloid deposits in mice had strongly positive immunohistochemical reactions with anti-mouse AA, and negative reaction with anti-human AA or anti-human prealbumin. The results lend support to the idea that accelerated amyloid induction in the recipient mice is unlikely to be due to transfer of human amyloid substance, but rather to formation of "native" murine amyloid under the influence of a human AEF factor similar to or identical with AEF described in mouse-to mouse transfer models.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2874651     DOI: 10.1007/bf02899027

Source DB:  PubMed          Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol        ISSN: 0340-6075


  11 in total

1.  Mutagenic exploration of the cross-seeding and fibrillation propensity of Alzheimer's beta-amyloid peptide variants.

Authors:  Alexander Peim; Peter Hortschansky; Tony Christopeit; Volker Schroeckh; Walter Richter; Marcus Fändrich
Journal:  Protein Sci       Date:  2006-06-02       Impact factor: 6.725

2.  Alzheimer's disease brain-derived ubiquitin has amyloid-enhancing factor activity: behavior of ubiquitin during accelerated amyloidogenesis.

Authors:  K Alizadeh-Khiavi; J Normand; S Chronopoulos; Z Ali-Khan
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

Review 3.  Disorder-to-order conformational transitions in protein structure and its relationship to disease.

Authors:  Paola Mendoza-Espinosa; Victor García-González; Abel Moreno; Rolando Castillo; Jaime Mas-Oliva
Journal:  Mol Cell Biochem       Date:  2009-04-09       Impact factor: 3.396

4.  Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis.

Authors:  G Merlini; E Ascari; N Amboldi; V Bellotti; E Arbustini; V Perfetti; M Ferrari; I Zorzoli; M G Marinone; P Garini
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

5.  Evidence for increased amyloid enhancing factor activity in Alzheimer brain extract.

Authors:  Z Ali-Khan; R Quirion; Y Robitaille; K Alizadeh-Khiavi; T Du
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

6.  Presence of glycosaminoglycans in purified AA type amyloid fibrils associated with juvenile rheumatoid arthritis.

Authors:  J H Magnus; G Husby; S O Kolset
Journal:  Ann Rheum Dis       Date:  1989-03       Impact factor: 19.103

7.  Amyloid enhancing factor (AEF) in the aging mouse.

Authors:  T Yokota; T Ishihara; H Kawano; M Takahashi; Y Fujinaga; F Uchino
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

8.  Effect of serum amyloid P component level on transthyretin-derived amyloid deposition in a transgenic mouse model of familial amyloidotic polyneuropathy.

Authors:  T Murakami; S Yi; S Maeda; F Tashiro; K Yamamura; K Takahashi; K Shimada; S Araki
Journal:  Am J Pathol       Date:  1992-08       Impact factor: 4.307

9.  Amyloid enhancing factor activity is associated with ubiquitin.

Authors:  K Alizadeh-Khiavi; J Normand; S Chronopoulos; A Ali; Z Ali-Khan
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

10.  Generation and characterization of anti-AA amyloid-specific monoclonal antibodies.

Authors:  Jonathan S Wall; Stephen J Kennel; Tina Richey; Amy Allen; Alan Stuckey; Deborah T Weiss; Sallie D Macy; Robin Barbour; Peter Seubert; Alan Solomon; Dale Schenk
Journal:  Front Immunol       Date:  2011-08-08       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.